NASDAQ:APM Aptorum Group (APM) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free APM Stock Alerts $4.60 -0.66 (-12.55%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$4.60▼$5.0050-Day Range$1.45▼$10.5552-Week Range$1.35▼$17.49Volume21,764 shsAverage Volume1.66 million shsMarket Capitalization$23.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Aptorum Group alerts: Email Address Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About Aptorum Group Stock (NASDAQ:APM)Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Read More APM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APM Stock News HeadlinesApril 30, 2024 | businesswire.comAptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business UpdateMarch 21, 2024 | finance.yahoo.comAptorum Group Limited (APM)March 12, 2024 | cnn.comAptorum Group Limited Class AMarch 6, 2024 | finance.yahoo.comAptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy BusinessMarch 6, 2024 | investorplace.com5 Investors Betting Big on Aptorum (APM) GroupMarch 6, 2024 | investorplace.comWhy Is Aptorum (APM) Stock Up 346% Today?February 22, 2024 | investing.comAptorum Group Ltd Class A (APM)December 30, 2023 | lse.co.ukAptorum Group Cl A Share ChatDecember 26, 2023 | seekingalpha.comAptorum Group GAAP EPS of -$1.43, revenue of $0.43MDecember 22, 2023 | finance.yahoo.comAptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023November 16, 2023 | finance.yahoo.comAptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023November 9, 2023 | morningstar.comAptorum Group Ltd Class A APMSeptember 14, 2023 | benzinga.comAutism Summit Garners Over 30,000 Attendees: APM Announces Date of its Upcoming ConferenceAugust 8, 2023 | finance.yahoo.comAPM - Aptorum Group LimitedJune 27, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaJune 22, 2023 | finance.yahoo.comAptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaJune 9, 2023 | finance.yahoo.comAptorum Group Limited Announces Voluntary Delisting from Euronext ParisMay 26, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity DeficiencyMay 5, 2023 | finance.yahoo.comAptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity DeficiencyMay 4, 2023 | msn.comWhy Arconic Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving PremarketMay 1, 2023 | finance.yahoo.comAptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations LimitedMay 1, 2023 | finance.yahoo.comAptorum Group Full Year 2022 Earnings: EPS Beats Expectations, Revenues LagApril 28, 2023 | finance.yahoo.comAptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business UpdateApril 25, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Announces Completion of $3 Million Convertible Note due 2023April 25, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Announces 1-for-10 Reverse Stock SplitSee More Headlines Receive APM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptorum Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/14/2024Next Earnings (Estimated)7/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APM CUSIPN/A CIK1734005 Webwww.aptorumgroup.com Phone442080929299FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.20 Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$430,000.00 Price / Sales58.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book1.64Miscellaneous Outstanding Shares5,180,000Free Float1,866,000Market Cap$25.28 million OptionableNot Optionable Beta0.85 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Chung Yuen Huen (Age 44)Founder, CEO & Non-Executive Director Comp: $923.66kMr. Martin Siu (Age 45)Head of Finance Comp: $87.34kKey CompetitorsOrgenesisNASDAQ:ORGSNeuroBo PharmaceuticalsNASDAQ:NRBONeuroSense TherapeuticsNASDAQ:NRSNFlora GrowthNASDAQ:FLGCGalectoNASDAQ:GLTOView All Competitors APM Stock Analysis - Frequently Asked Questions How have APM shares performed in 2024? Aptorum Group's stock was trading at $2.45 at the beginning of the year. Since then, APM shares have increased by 87.8% and is now trading at $4.60. View the best growth stocks for 2024 here. When is Aptorum Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 30th 2024. View our APM earnings forecast. When did Aptorum Group's stock split? Aptorum Group's stock reverse split on the morning of Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Aptorum Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptorum Group investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Micron Technology (MU), Aridis Pharmaceuticals (ARDS). How do I buy shares of Aptorum Group? Shares of APM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APM) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.